开放标签、多中心、剂量递增II期临床试验:tadekinig alfa(IL-18BP)治疗成人起病Still病的安全性与疗效
这项II期开放标签多中心剂量递增研究纳入活动性成人起病Still病患者,接受tadekinig alfa 80 mg或160 mg皮下注射每周三次共12周,80 mg组未达早期预测缓解标准者上调至160 mg再治疗12周,主要终点为全程不良事件发生情况。结果显示tadekinig alfa似乎具有良好安全性特征,并与早期疗效信号相关。
要点
- 10例接受80 mg、13例接受160 mg tadekinig alfa皮下注射每周三次。
- 共记录155例治疗中出现的不良事件,其中47例被认为与研究药物相关。
- 第3周时80 mg组10例中5例、160 mg组12例中6例达到预设缓解标准。
核心结论
- 结果表明tadekinig alfa似乎具有良好安全性特征,并在成人起病Still病患者中与早期疗效信号相关。
研究设计与样本
- II期开放标签研究,纳入年龄≥18岁、尽管接受泼尼松和/或传统合成改善病情抗风湿药治疗仍存在活动性成人起病Still病伴发热或C反应蛋白≥10 mg/L的患者,允许既往生物制剂改善病情抗风湿药治疗。
- 患者接受tadekinig alfa 80 mg或160 mg皮下注射每周三次共12周,80 mg组未达到早期预测缓解标准(C反应蛋白较基线下降≥50%且发热消退)者上调至160 mg再治疗12周。
- 主要终点为整个研究期间不良事件的发生情况。
主要发现
- 10例患者分配至80 mg tadekinig alfa组,13例分配至160 mg剂量组。
- 共记录155例治疗中出现的不良事件,其中47例被认为与研究药物相关,大多数不良事件为轻度并在停药后缓解。
- 发生3例严重不良事件,其中1例可能与治疗相关(中毒性视神经病变)。
- 第3周时,80 mg组10例中5例、160 mg组12例中6例达到预设缓解标准。
关键数值与推荐
- 早期预测缓解标准为C反应蛋白较基线下降≥50%且发热消退。
- 入组要求尽管接受泼尼松和/或传统合成改善病情抗风湿药治疗,仍存在发热或C反应蛋白≥10 mg/L。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Adult-onset Still's disease (AOSD) is a rare systemic autoinflammatory disease; its management is largely empirical. This is the first clinical study to determine if interleukin (IL)-18 inhibition, using the recombinant human IL-18 binding protein, tadekinig alfa, is a therapeutic option in AOSD. METHODS: In this phase II, open-label study, patients were ≥18 years with active AOSD plus fever or C reactive protein (CRP) levels ≥10 mg/L despite treatment with prednisone and/or conventional synthetic disease-modifying antirheumatic drugs (DMARDs). Previous biological DMARD treatment was permitted. Patients received tadekinig alfa 80 mg or 160 mg subcutaneously three times per week for 12 weeks; those receiving 80 mg not achieving early predicted response criteria (reduction of ≥50% CRP values from baseline and fever resolution) were up-titrated to 160 mg for a further 12 weeks. The primary endpoint was the occurrence of adverse events (AEs) throughout the study. RESULTS: Ten patients were assigned to receive 80 mg tadekinig alfa and 13 patients to the 160 mg dose. One hundred and fifty-five treatment-emerging AEs were recorded, and 47 were considered related to the study drug. Most AEs were mild and resolved after drug discontinuation. Three serious AEs occurred, one possibly related to treatment (toxic optic neuropathy). At week 3, 5 of 10 patients receiving 80 mg and 6 of 12 patients receiving 160 mg achieved the predefined response criteria. CONCLUSIONS: Our results indicate that tadekinig alfa appears to have a favourable safety profile and is associated with early signs of efficacy in patients with AOSD. TRIAL REGISTRATION NUMBER: NCT02398435.
引用
- Gabay C, Fautrel B, Rech J, et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. Ann Rheum Dis. 2018. PMID: 29472362. doi:10.1136/annrheumdis-2017-212608
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。